JPM: CVS says Medicare Advantage patients are impacting profits

WilfredoLee/APMedicareAdvantagememberscontinuetogotothedoctorandgethealthcareproceduresalotmorethanp PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year




fashion

author：explore    Page View：243
Rod Nathan, Ali Urman, and Patrick Nosker on the 2024 Breakthrough Summit East stage.
From left, Rod Nathan, portfolio manager and partner of J. Goldman & Co.; ARK Invest senior analyst Ali Urman; and Patrick Nosker, director of research and partner at Affinity Asset Advisors, discuss biotech investment opportunities at the 2024 STAT Breakthrough Summit East. STAT

Following a blockbuster year of dealmaking and a recent uptick in biotech stocks, top investors see more good news on the horizon.

Driving the momentum? Economics 101.

advertisement

Biotechs rely on borrowing capital, which is a more tenuous task when interest rates are high. But interest rates have most likely peaked, with Federal Reserve officials signaling earlier this week they expected to make three cuts this year. For public biotechnology startups that have been battered by the market in recent years, this is a very good thing, Rod Nathan, portfolio manager and partner of J. Goldman & Co., said on a panel at STAT’s Breakthrough Summit East in New York on Thursday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： How a scoliosis diagnosis changed the life of one young dancer
Next article： New air purifier tech could be key to improving indoor air quality